Seattle Genetics Company Profile (NASDAQ:SGEN)

About Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics logoSeattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:SGEN
  • CUSIP: 81257810
  • Web: www.seattlegenetics.com
Capitalization:
  • Market Cap: $7.72183 billion
  • Outstanding Shares: 142,716,000
Average Prices:
  • 50 Day Moving Avg: $58.25
  • 200 Day Moving Avg: $62.04
  • 52 Week Range: $42.58 - $75.36
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -50.83
  • P/E Growth: -0.02
Sales & Book Value:
  • Annual Revenue: $416.12 million
  • Price / Sales: 18.65
  • Book Value: $4.23 per share
  • Price / Book: 12.86
Profitability:
  • EBIDTA: ($162,430,000.00)
  • Net Margins: -43.17%
  • Return on Equity: -27.98%
  • Return on Assets: -21.54%
Debt:
  • Current Ratio: 5.09%
  • Quick Ratio: 4.62%
Misc:
  • Average Volume: 1.07 million shs.
  • Beta: 2.4
  • Short Ratio: 14.32
 
Frequently Asked Questions for Seattle Genetics (NASDAQ:SGEN)

What is Seattle Genetics' stock symbol?

Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."

How were Seattle Genetics' earnings last quarter?

Seattle Genetics, Inc. (NASDAQ:SGEN) announced its quarterly earnings data on Thursday, April, 27th. The company reported ($0.42) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.01. The company earned $109.10 million during the quarter, compared to analyst estimates of $103.23 million. Seattle Genetics had a negative net margin of 43.17% and a negative return on equity of 27.98%. The firm's revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter last year, the business earned ($0.15) EPS. View Seattle Genetics' Earnings History.

When will Seattle Genetics make its next earnings announcement?

Seattle Genetics is scheduled to release their next quarterly earnings announcement on Monday, July, 24th 2017. View Earnings Estimates for Seattle Genetics.

Where is Seattle Genetics' stock going? Where will Seattle Genetics' stock price be in 2017?

19 analysts have issued 1 year price objectives for Seattle Genetics' stock. Their predictions range from $38.00 to $80.00. On average, they expect Seattle Genetics' stock price to reach $60.46 in the next twelve months. View Analyst Ratings for Seattle Genetics.

What are analysts saying about Seattle Genetics stock?

Here are some recent quotes from research analysts about Seattle Genetics stock:

  • 1. Cantor Fitzgerald analysts commented, "The Phase III ECHELON-1 study in previously untreated patients with advanced classical Hodgkin lymphoma met its primary endpoint of modified PFS (82.1% versus 77.2% at two years)." (6/26/2017)
  • 2. Cowen and Company analysts commented, "SGEN announced this morning that following an interim safety look of 33A’s pivotal." (6/19/2017)
  • 3. Cann analysts commented, "Seattle Genetics announced today that it is discontinuing the phase III CASCADE clinical trial of vadastuximab talirine (SGN-CD33A) in frontline older acute myeloid leukemia (AML) patients. Seattle Genetics reported it took this action following consultation with the Independent Data Monitoring Committee (IDMC) and after reviewing unblinded data on June 16, 2017. As a result of the discontinuation of SGN-CD33A (vadastuximab talirine; 33A), we are removing estimated sales of SGN- CD33A from our model in 2020 and 2021." (6/19/2017)
  • 4. J P Morgan Chase & Co analysts commented, "With top-line results for ECHELON-1 (Adcetris in 1L Hodgkin lymphoma) reading out at some point in 2017, we conducted a detailed analysis of the trial design and available data and interviewed a couple more KOLs to help frame expectations. We are also updating our model to better account for doc feedback and re-treatment rates among the various approved Adcetris settings. The bottom line is that we are bullish on the potential success of E-1 (70% in our model), which may offer a favorable trading opportunity into the data." (6/13/2017)
  • 5. According to Zacks Investment Research, "Seattle Genetics missed bottom-line expectations in the first quarter of 2017 but sales came in ahead of estimates. With the recent llabel expansion of Keytruda in the lymphoma indication, investor focus will likely remain on Adcetris sales in the upcoming quarters. A decline in Adcetris sales will hurt the company's top line. Though, the company has a number of candidates in its pipeline, most of them are in early stages of development. Although the clinical hold on several early-stage trials of vadastuximab talirine in acute myeloid leukemia (AML) was lifted in Mar 2017, Seattle Genetics has a long way to go before the candidate comes close to commercialization. However, the company’s collaboration agreement with Takeda for the global development and commercialization of Adcetris is encouraging. Also, collaborations with companies like AbbVie, Bayer, Roche and Pfizer provide it with funds in the form of upfront, milestone and other payments." (5/2/2017)

Who are some of Seattle Genetics' key competitors?

Who are Seattle Genetics' key executives?

Seattle Genetics' management team includes the folowing people:

  • Clay B. Siegall Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Todd E. Simpson, Chief Financial Officer
  • Eric L. Dobmeier, Chief Operating Officer
  • Jean I. Liu J.D., Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
  • Darren S. Cline, Executive Vice President - Commercial
  • Jonathan G. Drachman M.D., Chief Medical Officer, Executive Vice President - Research and Development
  • Vaughn B. Himes Ph.D., Chief Technical Officer
  • Felix J. Baker Ph.D., Lead Independent Director
  • Srinivas Akkaraju M.D. Ph.D., Independent Director
  • David W. Gryska, Independent Director

Who owns Seattle Genetics stock?

Seattle Genetics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BAKER BROS. ADVISORS LP (32.20%), Creative Planning (0.03%), Aperio Group LLC (0.02%), Capital Impact Advisors LLC (0.02%), Eqis Capital Management Inc. (0.02%) and Berson & Corrado Investment Advisors LLC (0.02%). Company insiders that own Seattle Genetics stock include Clay B Siegall, Darren S Cline, David W Gryska, Eric Dobmeier, Felix Baker, John A Orwin, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Institutional Ownership Trends for Seattle Genetics.

Who sold Seattle Genetics stock? Who is selling Seattle Genetics stock?

Seattle Genetics' stock was sold by a variety of institutional investors in the last quarter, including Creative Planning, Capital Impact Advisors LLC, Xact Kapitalforvaltning AB and Capstone Asset Management Co.. Company insiders that have sold Seattle Genetics stock in the last year include Clay B Siegall, Darren S Cline, Eric Dobmeier, Jonathan G Drachman, Marc E Lippman and Vaughn B Himes. View Insider Buying and Selling for Seattle Genetics.

Who bought Seattle Genetics stock? Who is buying Seattle Genetics stock?

Seattle Genetics' stock was bought by a variety of institutional investors in the last quarter, including Mn Services Vermogensbeheer B.V., Fox Run Management L.L.C., US Bancorp DE, Meeder Asset Management Inc., Quantitative Systematic Strategies LLC, Assenagon Asset Management S.A., Berson & Corrado Investment Advisors LLC and Atria Investments LLC. Company insiders that have bought Seattle Genetics stock in the last two years include Felix Baker and John A Orwin. View Insider Buying and Selling for Seattle Genetics.

How do I buy Seattle Genetics stock?

Shares of Seattle Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Seattle Genetics' stock price today?

One share of Seattle Genetics stock can currently be purchased for approximately $54.39.


MarketBeat Community Rating for Seattle Genetics (NASDAQ SGEN)
Community Ranking:  2.3 out of 5 ( )
Outperform Votes:  264 (Vote Outperform)
Underperform Votes:  310 (Vote Underperform)
Total Votes:  574
MarketBeat's community ratings are surveys of what our community members think about Seattle Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Seattle Genetics (NASDAQ:SGEN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Sell Ratings, 10 Hold Ratings, 6 Buy Ratings
Consensus Rating:Hold (Score: 2.16)
Consensus Price Target: $60.46 (11.16% upside)

Analysts' Ratings History for Seattle Genetics (NASDAQ:SGEN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
6/27/2017J P Morgan Chase & CoReiterated RatingNeutralHighView Rating Details
6/27/2017Piper Jaffray CompaniesReiterated RatingNeutral$48.00HighView Rating Details
6/26/2017Cantor FitzgeraldReiterated RatingHold$43.00HighView Rating Details
6/23/2017Barclays PLCReiterated RatingHoldMediumView Rating Details
6/21/2017Morgan StanleyLower Price TargetOverweight$70.00 -> $64.00MediumView Rating Details
6/20/2017Needham & Company LLCReiterated RatingBuy$72.00LowView Rating Details
6/19/2017Cowen and CompanyReiterated RatingHold$61.00 -> $54.00HighView Rating Details
6/19/2017CannReiterated RatingHoldLowView Rating Details
6/15/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldMediumView Rating Details
4/28/2017HC WainwrightBoost Price TargetBuy$65.00 -> $75.00LowView Rating Details
4/7/2017Leerink SwannBoost Price TargetOutperform$70.00 -> $74.00MediumView Rating Details
3/16/2017CIBCInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
2/16/2017Bank of America CorporationDowngradeNeutral -> UnderperformN/AView Rating Details
2/13/2017Credit Suisse Group AGBoost Price TargetNeutral$62.00 -> $66.00N/AView Rating Details
1/5/2017Royal Bank Of CanadaSet Price TargetBuy$80.00N/AView Rating Details
1/5/2017Maxim GroupReiterated RatingReduceN/AView Rating Details
9/16/2016Goldman Sachs Group, Inc. (The)DowngradeNeutral -> SellN/AView Rating Details
7/27/2016SunTrust Banks, Inc.Boost Price TargetNeutral$34.00 -> $38.00N/AView Rating Details
(Data available from 7/22/2015 forward)

Earnings

Earnings History for Seattle Genetics (NASDAQ:SGEN)
Earnings by Quarter for Seattle Genetics (NASDAQ:SGEN)
Earnings History by Quarter for Seattle Genetics (NASDAQ SGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/24/2017        
4/27/2017Q1 2017($0.41)($0.42)$103.23 million$109.10 millionViewN/AView Earnings Details
2/9/2017Q416($0.34)($0.39)$106.49 million$105.30 millionViewListenView Earnings Details
10/27/2016Q316($0.29)($0.23)$4.34 million$106.30 millionViewListenView Earnings Details
7/26/2016Q216($0.32)($0.23)$94.56 million$95.40 millionViewListenView Earnings Details
4/28/2016Q116($0.09)($0.15)$116.49 million$111.15 millionViewListenView Earnings Details
2/9/2016Q415($0.20)($0.18)$88.00 million$93.50 millionViewN/AView Earnings Details
10/29/2015Q315($0.20)($0.21)$82.35 million$84.10 millionViewListenView Earnings Details
7/30/2015Q215($0.26)($0.38)$78.21 million$77.10 millionViewListenView Earnings Details
4/30/2015Q1($0.19)($0.17)$74.57 million$82.20 millionViewListenView Earnings Details
2/10/2015Q414($0.25)($0.22)$68.34 million$74.30 millionViewListenView Earnings Details
10/30/2014Q314($0.24)($0.13)$66.90 million$75.80 millionViewListenView Earnings Details
7/31/2014Q214($0.23)($0.14)$65.04 million$68.30 millionViewListenView Earnings Details
5/1/2014Q114($0.21)($0.13)$64.62 million$68.30 millionViewListenView Earnings Details
2/11/2014Q413($0.24)($0.13)$59.50 million$67.40 millionViewListenView Earnings Details
11/5/2013Q313($0.22)($0.19)$57.79 million$71.00 millionViewListenView Earnings Details
7/31/2013Q2 2013($0.20)($0.06)$58.12 million$773.60 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.19)($0.14)$53.72 million$57.32 millionViewListenView Earnings Details
2/12/2013Q4 2012($0.10)($0.09)$57.21 million$63.90 millionViewListenView Earnings Details
11/7/2012Q312($0.14)($0.12)$52.79 million$49.83 millionViewN/AView Earnings Details
8/8/2012($0.15)($0.15)ViewN/AView Earnings Details
5/8/2012($0.11)($0.11)ViewN/AView Earnings Details
2/13/2012($0.31)($0.24)ViewN/AView Earnings Details
11/3/2011($0.46)($0.35)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Seattle Genetics (NASDAQ:SGEN)
2017 EPS Consensus Estimate: ($1.47)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.39)($0.39)($0.39)
Q2 20173($0.44)($0.28)($0.37)
Q3 20174($0.47)($0.19)($0.34)
Q4 20174($0.50)($0.23)($0.37)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Seattle Genetics (NASDAQ:SGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Seattle Genetics (NASDAQ:SGEN)
Insider Ownership Percentage: 33.30%
Institutional Ownership Percentage: 98.04%
Insider Trades by Quarter for Seattle Genetics (NASDAQ:SGEN)
Institutional Ownership by Quarter for Seattle Genetics (NASDAQ:SGEN)
Insider Trades by Quarter for Seattle Genetics (NASDAQ:SGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/5/2017Clay B. SiegallCEOSell10,423$51.98$541,787.54View SEC Filing  
6/22/2017Jonathan G DrachmanCMOSell10,000$64.01$640,100.00View SEC Filing  
6/5/2017Clay B. SiegallInsiderSell10,423$65.21$679,683.83View SEC Filing  
4/5/2017Clay B SiegallInsiderSell14,465$62.99$911,150.35View SEC Filing  
3/31/2017Vaughn B HimesInsiderSell10,000$62.75$627,500.00View SEC Filing  
3/6/2017Clay B SiegallCEOSell14,465$68.04$984,198.60View SEC Filing  
2/6/2017Clay B SiegallInsiderSell14,465$61.54$890,176.10View SEC Filing  
1/6/2017Clay B. SiegallInsiderSell14,465$57.89$837,378.85View SEC Filing  
12/13/2016Darren S. ClineEVPSell10,000$63.38$633,800.00View SEC Filing  
12/8/2016Eric DobmeierCOOSell12,500$65.92$824,000.00View SEC Filing  
12/7/2016Vaughn B. HimesInsiderSell30,000$65.32$1,959,600.00View SEC Filing  
11/8/2016Felix BakerDirectorBuy382,500$59.36$22,705,200.00View SEC Filing  
11/7/2016Clay B. SiegallCEOSell14,465$58.43$845,189.95View SEC Filing  
11/7/2016Marc E. LippmanDirectorSell1,000$57.75$57,750.00View SEC Filing  
11/3/2016Felix BakerDirectorBuy1,030,629$56.13$57,849,205.77View SEC Filing  
11/1/2016Jonathan G. DrachmanCMOSell3,418$51.74$176,847.32View SEC Filing  
10/6/2016Clay B. SiegallInsiderSell14,465$54.41$787,040.65View SEC Filing  
9/22/2016Jonathan G DrachmanCMOSell2,249$56.75$127,630.75View SEC Filing  
9/14/2016Eric DobmeierCOOSell22,918$54.04$1,238,488.72View SEC Filing  
9/13/2016Felix BakerDirectorBuy447,311$50.71$22,683,140.81View SEC Filing  
9/8/2016Clay B. SiegallInsiderSell31,269$50.08$1,565,951.52View SEC Filing  
9/8/2016Felix BakerDirectorBuy414,016$48.43$20,050,794.88View SEC Filing  
8/23/2016Eric DobmeierCOOSell12,589$48.00$604,272.00View SEC Filing  
8/22/2016Clay B. SiegallInsiderSell23,381$46.59$1,089,320.79View SEC Filing  
8/22/2016Eric DobmeierCOOSell5,411$46.59$252,098.49View SEC Filing  
8/22/2016Vaughn B. HimesEVPSell3,991$46.59$185,940.69View SEC Filing  
8/8/2016Clay B. SiegallInsiderSell11,660$47.19$550,235.40View SEC Filing  
7/27/2016Clay B. SiegallInsiderSell4,042$45.20$182,698.40View SEC Filing  
7/6/2016Clay B. SiegallCEOSell7,618$40.56$308,986.08View SEC Filing  
6/6/2016Clay B SiegallCEOSell22,083$43.59$962,597.97View SEC Filing  
6/2/2016Darren S ClineEVPSell3,366$42.07$141,607.62View SEC Filing  
5/27/2016Clay B SiegallCEOSell48,660$40.41$1,966,350.60View SEC Filing  
5/24/2016Clay B SiegallCEOSell8,400$40.09$336,756.00View SEC Filing  
5/23/2016Clay B SiegallCEOSell6,700$40.12$268,804.00View SEC Filing  
5/17/2016Clay B SiegallCEOSell7,618$35.16$267,848.88View SEC Filing  
4/25/2016Clay B SiegallCEOSell800$40.00$32,000.00View SEC Filing  
4/5/2016Clay B SiegallCEOSell7,618$36.12$275,162.16View SEC Filing  
3/22/2016Clay B SiegallCEOSell15,236$35.52$541,182.72View SEC Filing  
3/21/2016Clay B SiegallCEOSell4,282$35.01$149,912.82View SEC Filing  
3/17/2016Felix BakerDirectorBuy124,065$31.85$3,951,470.25View SEC Filing  
3/16/2016Felix BakerDirectorBuy1,349,237$32.10$43,310,507.70View SEC Filing  
3/15/2016Felix BakerDirectorBuy661,093$32.08$21,207,863.44View SEC Filing  
3/14/2016Felix BakerDirectorBuy118,941$33.77$4,016,637.57View SEC Filing  
3/11/2016Felix BakerDirectorBuy694,666$32.46$22,548,858.36View SEC Filing  
3/8/2016Felix BakerDirectorBuy502,523$22.66$11,387,171.18View SEC Filing  
3/2/2016Felix BakerDirectorBuy675,922$31.77$21,474,041.94View SEC Filing  
3/1/2016Felix BakerDirectorBuy24,200$31.24$756,008.00View SEC Filing  
2/29/2016Felix BakerDirectorBuy251,722$30.39$7,649,831.58View SEC Filing  
2/26/2016Felix BakerDirectorBuy314,508$29.55$9,293,711.40View SEC Filing  
2/22/2016Felix BakerDirectorBuy1,001,471$29.63$29,673,585.73View SEC Filing  
2/17/2016Felix BakerDirectorBuy1,269,147$30.43$38,620,143.21View SEC Filing  
2/12/2016John A. OrwinDirectorBuy2,000$28.33$56,660.00View SEC Filing  
12/15/2015Vaughn B. HimesEVPSell40,500$39.94$1,617,570.00View SEC Filing  
12/3/2015Clay B. SiegallCEOSell3,720$39.99$148,762.80View SEC Filing  
11/20/2015Felix BakerDirectorBuy329,358$43.94$14,471,990.52View SEC Filing  
11/17/2015Clay B SiegallCEOSell87,473$45.40$3,971,274.20View SEC Filing  
11/11/2015Darren S ClineSVPSell5,769$45.68$263,527.92View SEC Filing  
11/10/2015Felix BakerDirectorBuy934,624$42.95$40,142,100.80View SEC Filing  
11/9/2015Felix BakerDirectorBuy507,300$43.76$22,199,448.00View SEC Filing  
11/6/2015Eric DobmeierCOOSell17,452$42.50$741,710.00View SEC Filing  
11/6/2015Felix BakerDirectorBuy417,924$41.94$17,527,732.56View SEC Filing  
11/5/2015David W GryskaDirectorSell10,000$43.57$435,700.00View SEC Filing  
11/4/2015Clay B. SiegallCEOSell3,718$43.14$160,394.52View SEC Filing  
10/5/2015Clay B. SiegallCEOSell3,718$41.30$153,553.40View SEC Filing  
9/3/2015Clay B. SiegallCEOSell3,718$40.12$149,166.16View SEC Filing  
8/20/2015Clay B. SiegallCEOSell31,754$42.02$1,334,303.08View SEC Filing  
8/20/2015Darren S. ClineSVPSell2,231$42.02$93,746.62View SEC Filing  
8/20/2015Eric DobmeierCOOSell8,548$42.02$359,186.96View SEC Filing  
8/20/2015Jonathan G. DrachmanCMOSell4,462$42.02$187,493.24View SEC Filing  
8/20/2015Todd E. SimpsonCFOSell5,825$42.02$244,766.50View SEC Filing  
8/20/2015Vaughn B. HimesEVPSell5,997$42.02$251,993.94View SEC Filing  
7/6/2015Clay B SiegallCEOSell3,718$46.94$174,522.92View SEC Filing  
6/3/2015Clay B SiegallCEOSell3,718$45.72$169,986.96View SEC Filing  
5/21/2015Felix BakerDirectorBuy950,886$42.49$40,403,146.14View SEC Filing  
5/8/2015Eric DobmeierCOOSell17,074$40.38$689,448.12View SEC Filing  
5/7/2015Felix BakerDirectorBuy1,032,664$35.56$36,721,531.84View SEC Filing  
3/10/2015Felix BakerDirectorBuy285,036$34.66$9,879,347.76View SEC Filing  
3/9/2015Felix BakerDirectorBuy275,717$34.66$9,556,351.22View SEC Filing  
3/4/2015Felix BakerDirectorBuy448,841$34.84$15,637,620.44View SEC Filing  
2/25/2015Felix BakerDirectorBuy281,115$33.92$9,535,420.80View SEC Filing  
1/6/2015Clay B SiegallCEOSell16,804$31.80$534,367.20View SEC Filing  
12/16/2014Felix BakerDirectorBuy2,883,378$31.86$91,864,423.08View SEC Filing  
12/10/2014Felix BakerDirectorBuy1,247,896$33.82$42,203,842.72View SEC Filing  
12/9/2014Felix BakerDirectorBuy128,430$34.16$4,387,168.80View SEC Filing  
12/8/2014Felix BakerDirectorBuy465,316$32.93$15,322,855.88View SEC Filing  
11/12/2014Vaughn B HimesEVPSell10,000$37.52$375,200.00View SEC Filing  
11/10/2014Felix BakerDirectorBuy1,653,925$34.56$57,159,648.00View SEC Filing  
9/4/2014Clay B SiegallCEOSell5,600$42.54$238,224.00View SEC Filing  
8/12/2014Clay B SiegallCEOSell11,200$40.38$452,256.00View SEC Filing  
8/11/2014Clay B SiegallCEOSell2,700$40.05$108,135.00View SEC Filing  
6/13/2014Felix BakerDirectorBuy216,595$39.92$8,646,472.40View SEC Filing  
6/10/2014Clay B SiegallCEOSell11,200$40.14$449,568.00View SEC Filing  
6/9/2014Felix BakerDirectorBuy546,252$38.16$20,844,976.32View SEC Filing  
6/4/2014Felix BakerDirectorBuy281,963$34.86$9,829,230.18View SEC Filing  
5/16/2014Felix BakerDirectorBuy189,611$34.07$6,460,046.77View SEC Filing  
4/3/2014Clay SiegallCEOSell5,600$43.34$242,704.00View SEC Filing  
2/18/2014Clay SiegallCEOSell100,000$51.97$5,197,000.00View SEC Filing  
1/21/2014Eric DobmeierCOOSell56,010$47.92$2,683,999.20View SEC Filing  
1/16/2014Jonathan DrachmanCMOSell1,201$45.75$54,945.75View SEC Filing  
12/16/2013Felix BakerDirectorBuy407,078$39.66$16,144,713.48View SEC Filing  
12/5/2013Felix BakerDirectorBuy1,005,901$43.19$43,444,864.19View SEC Filing  
10/1/2013Clay B SiegallCEOSell2,000$43.87$87,740.00View SEC Filing  
9/10/2013Eric DobmeierCOOSell42,000$46.40$1,948,800.00View SEC Filing  
9/5/2013Eric DobmeierCOOSell75,000$42.64$3,198,000.00View SEC Filing  
9/3/2013Clay B SiegallCEOSell102,000$43.90$4,477,800.00View SEC Filing  
9/3/2013David W GryskaDirectorSell10,000$42.48$424,800.00View SEC Filing  
8/27/2013Todd SimpsonCFOSell37,763$41.45$1,565,276.35View SEC Filing  
8/19/2013Clay SiegallCEOSell7,653$40.91$313,084.23View SEC Filing  
8/19/2013Eric DobmeierCOOSell3,328$40.91$136,148.48View SEC Filing  
8/19/2013Vaughn HimesEVPSell1,736$40.91$71,019.76View SEC Filing  
8/1/2013Clay B SiegallCEOSell2,000$40.03$80,060.00View SEC Filing  
7/12/2013Todd E SimpsonCFOSell92,527$37.45$3,465,136.15View SEC Filing  
7/1/2013Clay B SiegallCEOSell2,000$32.59$65,180.00View SEC Filing  
6/14/2013Srinivas AkkarajuDirectorSell5,000$32.75$163,750.00View SEC Filing  
6/13/2013Vaughn B HimesEVPSell10,000$32.11$321,100.00View SEC Filing  
6/3/2013Clay B SiegallCEOSell2,000$33.88$67,760.00View SEC Filing  
5/10/2013Srinivas AkkarajuDirectorSell17,500$37.17$650,475.00View SEC Filing  
3/6/2013Eric DobmeierCOOSell100,000$29.68$2,968,000.00View SEC Filing  
2/25/2013David W GryskaDirectorSell10,000$27.17$271,700.00View SEC Filing  
2/1/2013Clay B SiegallCEOSell2,000$29.61$59,220.00View SEC Filing  
1/15/2013Thomas C ReynoldsInsiderSell125,079$28.00$3,502,212.00View SEC Filing  
11/1/2012Clay B SiegallCEOSell8,250$25.51$210,457.50View SEC Filing  
9/4/2012Clay B SiegallCEOSell8,250$26.54$218,955.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Seattle Genetics (NASDAQ:SGEN)
Latest Headlines for Seattle Genetics (NASDAQ:SGEN)
Source:
DateHeadline
americanbankingnews.com logo$107.20 Million in Sales Expected for Seattle Genetics, Inc. (SGEN) This Quarter
www.americanbankingnews.com - July 19 at 4:54 PM
americanbankingnews.com logo Analysts Expect Seattle Genetics, Inc. (SGEN) to Announce -$0.43 EPS
www.americanbankingnews.com - July 17 at 10:54 AM
americanbankingnews.com logoResearch Analysts Set Expectations for Seattle Genetics, Inc.'s Q3 2017 Earnings (SGEN)
www.americanbankingnews.com - July 17 at 8:11 AM
americanbankingnews.com logoSeattle Genetics, Inc. (NASDAQ:SGEN) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - July 14 at 9:06 AM
americanbankingnews.com logoInsider Selling: Seattle Genetics, Inc. (NASDAQ:SGEN) CEO Sells 10,423 Shares of Stock
www.americanbankingnews.com - July 7 at 8:16 PM
finance.yahoo.com logoSeattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter Financial Results on July 27, 2017
finance.yahoo.com - July 6 at 8:55 AM
americanbankingnews.com logoFY2018 EPS Estimates for Seattle Genetics, Inc. Lowered by Analyst (SGEN)
www.americanbankingnews.com - June 29 at 11:36 AM
americanbankingnews.com logoBidaskClub Lowers Seattle Genetics, Inc. (SGEN) to Sell
www.americanbankingnews.com - June 28 at 4:56 PM
nasdaq.com logoFBT's Underlying Holdings Could Mean 11% Gain Potential - Nasdaq
www.nasdaq.com - June 28 at 3:23 PM
nasdaq.com logoSeattle Genetics (SGEN) Reports Positive Data for Adcetris - Nasdaq
www.nasdaq.com - June 28 at 8:18 AM
americanbankingnews.com logoSeattle Genetics' (SGEN) Outperform Rating Reiterated at William Blair
www.americanbankingnews.com - June 28 at 7:32 AM
americanbankingnews.com logoAnalysts Issue Forecasts for Seattle Genetics, Inc.'s Q2 2017 Earnings (SGEN)
www.americanbankingnews.com - June 28 at 7:24 AM
News IconUPDATE 1-Seattle Genetics, Takeda lymphoma drug success fails
www.businessinsider.com - June 28 at 12:51 AM
finance.yahoo.com logoSeattle Genetics (SGEN) Reports Positive Data for Adcetris
finance.yahoo.com - June 27 at 7:51 PM
News IconUPDATE 2-Seattle Genetics slumps as cancer drug data fails to impress
www.businessinsider.com - June 27 at 8:15 AM
streetinsider.com logoForm 8-K SEATTLE GENETICS INC For: Jun 26
www.streetinsider.com - June 27 at 8:15 AM
rttnews.com logoSeattle Genetics Inc. (SGEN) Dropped After Phase 3 Study Results Released
www.rttnews.com - June 27 at 8:15 AM
bizjournals.com logoSeattle Genetics preps for FDA approval of cancer drug that could push sales past $1B
www.bizjournals.com - June 27 at 8:15 AM
finance.yahoo.com logoJ.P. Morgan Gives Thoughts on Seattle Genetics, Inc. (SGEN) Following Phase 3 Results
finance.yahoo.com - June 27 at 8:15 AM
finance.yahoo.com logoSeattle Genetics slumps as cancer drug data fails to impress
finance.yahoo.com - June 27 at 8:15 AM
nasdaq.com logoSeattle Genetics Enters Oversold Territory (SGEN) - Nasdaq
www.nasdaq.com - June 27 at 8:15 AM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: Exelixis and Seattle Genetics
finance.yahoo.com - June 27 at 8:15 AM
americanbankingnews.com logoJ P Morgan Chase & Co Reiterates "Neutral" Rating for Seattle Genetics, Inc. (SGEN)
www.americanbankingnews.com - June 27 at 8:06 AM
americanbankingnews.com logoJonathan G. Drachman Sells 10,000 Shares of Seattle Genetics, Inc. (SGEN) Stock
www.americanbankingnews.com - June 26 at 7:39 PM
fool.com logoWhy Frontier Communications, Seattle Genetics, and Arconic Slumped Today
www.fool.com - June 26 at 5:07 PM
fool.com logoWhy Shares of Seattle Genetics, Inc. Got Whacked Today
www.fool.com - June 26 at 2:16 PM
americanbankingnews.com logoSeattle Genetics' (SGEN) Hold Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - June 26 at 10:31 AM
americanbankingnews.com logoSeattle Genetics' (SGEN) Hold Rating Reiterated at Barclays PLC
www.americanbankingnews.com - June 23 at 11:35 AM
streetinsider.com logoSeattle Genetics (SGEN) Announces Submission of Supplemental Biologics License ...
www.streetinsider.com - June 22 at 6:21 PM
reuters.com logoBRIEF-Seattle Genetics submits supplemental biologics license application to fda for Adcetris
www.reuters.com - June 22 at 6:21 PM
finance.yahoo.com logoSeattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma
finance.yahoo.com - June 22 at 6:21 PM
finance.yahoo.com logoSeattle Genetics (SGEN) Submits BLA to FDA for Cancer Drug
finance.yahoo.com - June 22 at 1:19 PM
americanbankingnews.com logoSeattle Genetics, Inc. (SGEN) Forecasted to Post Q3 2017 Earnings of ($0.19) Per Share
www.americanbankingnews.com - June 22 at 8:34 AM
americanbankingnews.com logoResearch Analysts Offer Predictions for Seattle Genetics, Inc.'s FY2020 Earnings (SGEN)
www.americanbankingnews.com - June 21 at 3:20 PM
americanbankingnews.com logoSeattle Genetics, Inc. (SGEN) Earns Overweight Rating from Morgan Stanley
www.americanbankingnews.com - June 21 at 10:04 AM
americanbankingnews.com logoSeattle Genetics, Inc. (SGEN) Expected to Post Earnings of -$0.44 Per Share
www.americanbankingnews.com - June 21 at 8:04 AM
streetinsider.com logoSeattle Genetics (SGEN) Announces Submission of Supplemental ... - StreetInsider.com
www.streetinsider.com - June 21 at 5:15 AM
americanbankingnews.com logoSeattle Genetics, Inc. (SGEN) Stock Rating Reaffirmed by J P Morgan Chase & Co
www.americanbankingnews.com - June 20 at 11:08 AM
americanbankingnews.com logoSeattle Genetics, Inc. (SGEN) Price Target Raised to $66.00 at Leerink Swann
www.americanbankingnews.com - June 20 at 8:10 AM
streetinsider.com logoNeedham & Company Reiterates Buy Rating and $72 PT on Seattle Genetics (SGEN) Following Discontinuation of ... - StreetInsider.com
www.streetinsider.com - June 20 at 7:17 AM
nasdaq.com logoAMGN's Xgeva To Face FDA In Feb, Double Treat For LPCN, SGEN ... - Nasdaq
www.nasdaq.com - June 20 at 7:17 AM
streetinsider.com logoSeattle Genetics (SGEN) Reports Discontinuation of Phase 3 CASCADE Trial of Vadastuximab Talirine (SGN-CD33A ... - StreetInsider.com
www.streetinsider.com - June 20 at 7:17 AM
marketwatch.com logoSeattle Genetics suspends trial of leukemia treatment after data showed higher rate of death - MarketWatch
www.marketwatch.com - June 20 at 7:17 AM
americanbankingnews.com logoCantor Fitzgerald Analysts Give Seattle Genetics, Inc. (SGEN) a $43.00 Price Target
www.americanbankingnews.com - June 19 at 3:16 PM
americanbankingnews.com logoSeattle Genetics, Inc. (SGEN) Given "Hold" Rating at Cowen and Company
www.americanbankingnews.com - June 19 at 1:32 PM
americanbankingnews.com logoSeattle Genetics, Inc. (SGEN) PT Lowered to $5.62 at Piper Jaffray Companies
www.americanbankingnews.com - June 19 at 11:34 AM
americanbankingnews.com logoSeattle Genetics' (SGEN) Hold Rating Reiterated at Cann
www.americanbankingnews.com - June 19 at 11:34 AM
reuters.com logoBRIEF-Seattle Genetics discontinues Phase 3 trial of vadastuximab talirine
www.reuters.com - June 19 at 9:44 AM
finance.yahoo.com logoSeattle Genetics Discontinues Phase 3 CASCADE Trial of Vadastuximab Talirine (SGN-CD33A) in Frontline Acute Myeloid Leukemia
finance.yahoo.com - June 19 at 9:44 AM
finance.yahoo.com logoSeattle Genetics suspends trial of leukemia treatment after data showed higher rate of death
finance.yahoo.com - June 19 at 9:44 AM

Social

Chart

Seattle Genetics (SGEN) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by MarketBeat.com Staff